Collectively, these data reveal that anti-TIGIT treatment during CA sepsis was associated with a reversal of immune cell loss and a decrease in the frequency of PD-1+ Treg and Teff in hosts with preexisting malignancy. This evidence concerns the gene TIGIT and cancer.